60 Degrees Pharmaceuticals Files 8-K
Ticker: SXTPW · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, SEC
TL;DR
60 Degrees Pharma filed an 8-K on Jan 8, 2025. No major news yet.
AI Summary
On January 8, 2025, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or transactions detailed in the provided text.
Why It Matters
This 8-K filing indicates that 60 Degrees Pharmaceuticals, Inc. has submitted required documentation to the SEC, which may contain updates on financial status or other corporate events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K submission and does not disclose any specific negative or positive material events.
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- January 8, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-41719 (identifier) — SEC File Number
- 45-2406880 (identifier) — IRS Employer Identification Number
- 1025 Connecticut Avenue NW Suite 1000 (address) — Principal Executive Office
- Washington, D.C. 20036 (address) — Principal Executive Office
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is primarily for 'Other Events' and 'Financial Statements and Exhibits', indicating routine corporate reporting.
When was this 8-K report filed?
The report was filed on January 8, 2025.
What is the exact name of the reporting company?
The exact name of the registrant is 60 DEGREES PHARMACEUTICALS, INC.
In which state was 60 Degrees Pharmaceuticals, Inc. incorporated?
The company was incorporated in Delaware.
What is the SEC file number for this company?
The SEC file number for 60 Degrees Pharmaceuticals, Inc. is 001-41719.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-01-08 16:05:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
Filing Documents
- ea0227197-8k_60degrees.htm (8-K) — 30KB
- ea022719701ex99-1_60degrees.htm (EX-99.1) — 28KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-25-002070.txt ( ) — 305KB
- sxtp-20250108.xsd (EX-101.SCH) — 4KB
- sxtp-20250108_def.xml (EX-101.DEF) — 26KB
- sxtp-20250108_lab.xml (EX-101.LAB) — 36KB
- sxtp-20250108_pre.xml (EX-101.PRE) — 25KB
- ea0227197-8k_60degrees_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On January 8, 2025, 60 Degrees Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it enrolled its first patient in NCT06478641, an expanded access clinical study intended to confirm the activity of tafenoquine in treating patients with persistent babesiosis who have failed standard of care treatment and are at high risk of experiencing a relapse. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release dated January 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: January 8, 2025 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 2